Lung Cancer
Volume 70, Issue 1 , Pages 43-50 , October 2010

Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma

  • Rabab Gaafar

      Affiliations

    • Medical Oncology Department, National Cancer Institute, Cairo University, Egypt
    • ,
  • Abeer Bahnassy

      Affiliations

    • Pathology Department, National Cancer Institute, Cairo University, Kaser El-Aini Str., Fom El-Khaleg, Cairo 11967, Egypt
    • Corresponding Author InformationCorresponding author. Tel.: +20 1 01720698/2 23664649; fax: +20 2 23644720.
    • ,
  • Ibrahim Abdelsalam

      Affiliations

    • Cancer Biology Department, National Cancer Institute, Cairo University, Egypt
    • ,
  • Mahmoud M. Kamel

      Affiliations

    • Clinical Pathology Department, National Cancer Institute, Cairo University, Egypt
    • ,
  • Amani Helal

      Affiliations

    • Medical Oncology Department, National Cancer Institute, Cairo University, Egypt
    • ,
  • Amany Abdel-Hamid

      Affiliations

    • Pathology Department, National Cancer Institute, Cairo University, Kaser El-Aini Str., Fom El-Khaleg, Cairo 11967, Egypt
    • ,
  • Nelly Aly Eldin

      Affiliations

    • Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Egypt
    • ,
  • Nadia Mokhtar

      Affiliations

    • Pathology Department, National Cancer Institute, Cairo University, Kaser El-Aini Str., Fom El-Khaleg, Cairo 11967, Egypt

Received 18 August 2009 ,Revised 15 December 2009 ,Accepted 4 January 2010.

References 

  1. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–672
  2. Edwards J, Swinson D, Jones J, Waller D, O’Byrne K. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer. 2006;54:399–407
  3. Gaafar R, Aly Eldin N. Epidemic of mesothelioma in Egypt. Lung Cancer. 2005;49:17–20
  4. Edwards J, Abrams K, Leverment J, Spyt T, Waller D, O’Byrne K. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55:731–735
  5. Ogino H, Yano S, Kakiuchi S, Yamada T, Ikuta K, Nakataki E, et al. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett. 2008;265(1):55–66
  6. Olayioye M, Neve R, Lane H, Hynes N. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–3167
  7. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7:2958–2970
  8. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–137
  9. Arteaga C. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist. 2002;7:31–39
  10. Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non small cell lung cancer. Int J Med Sci. 2008;5:209–217
  11. Sasaki H, Yukive H, Mizuno K, et al. Elevated serum epidermal growth factor receptor levels is correlated with lymph node metastasis in lung cancer. Int J Clin Oncol. 2003;8:79–82
  12. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550–6565
  13. Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M, et al. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol. 2008;
  14. Garland L, Rankin C, Gandara D, Rivkin S, Scott K, Nagle R, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007;25:2406–2413
  15. Destro A, Ceresoli G, Falleni M, Zucali P, Morenghi E, Bianchi P, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 2006;51:207–215
  16. Ambs KE, Takahahi A, Herring F, et al. Epidermal growth factor receptor in adenocarcinoma of the kidney. Urol Res. 1989;17:251–254
  17. Choi JH, Oh JY, Ruy SK, et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer. 1997;79:1879–1883
  18. Zekri A-RN, Bahnassy A, Mohamed WS, Hassan NA, Abdel-Rahman MA, Abou-El-Kasem F, et al. Evaluation of siamian virus as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma. Pathol Int. 2007;57:493–501
  19. IMIG: Please add it.
  20. Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. 2007; 20(10):1028–1035.
  21. Betta P-G, Libener R, Orecchia S, Bottero G, Filiberti R, Paganuzzi M, et al. Serum hepatocyte growth factor (HGF), epidermal growth factor (EGF), and stem cell factor (SCF) in pleural malignant mesothelioma. Proc ASCO. 2002;21:444a
  22. Schneider J, Presek P, Braun A, Bauer P, Konietzko N, Wiesner B, et al. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. Br J Cancer. 1999;80:1987–1994
  23. Govindan R, Ritter J, Suppiah R. EGFR and HER-2 overexpression in malignant mesothelioma. Proc Am Soc Clin Oncol. 2001;20:3106
  24. Garland L, Rankin C, Scott K, Nagle R, Lobell M, Gandara D, et al. Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma. Proc ASCO. 2004;22:3007
  25. Govindan R, Kratzke R, hernodon J, Neihans G, Vollmer R, Watson G, et al. Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11:2300–2304
  26. Watzka S, Setinek U, Huber M, Cantonati H, Lax F, Watson S, et al. Reactivity of integrin-linked kinase in human mesothelial cell proliferation. Interact Cardiovasc Thorac Surg. 2008;7:107–110
  27. O’Byrne K, Edwards J, Waller D. Clinicopathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer. 2004;45S:S45–S48
  28. Dazzi H, Hasleton P, Thatcher N, Wilkes S, Swindell R, Chatterjee A. Malignant pleural mesothelioma and epidermal growth factor receptor. Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer. 1990;61:924–926
  29. Janne P, Taffaro M, Salgia R, Johnson B. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002;62:5242–5247
  30. Cole G, Alleva A, Reddy R, Maxhimer J, Zuo J, Schrump D, et al. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD 153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2005;129:1010–1017

PII: S0169-5002(10)00004-8

doi: 10.1016/j.lungcan.2010.01.002

Lung Cancer
Volume 70, Issue 1 , Pages 43-50 , October 2010

Article Tools

* Image Usage & Resolution